Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2016 August;107(4) > Minerva Medica 2016 August;107(4):251-8

CURRENT ISSUEMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

REVIEWS  


Minerva Medica 2016 August;107(4):251-8

language: English

Long non-coding RNA H19 can predict a poor prognosis and lymph node metastasis: a meta-analysis in human cancer

Tao CHEN 1, Peng YANG 1, Zhen Y. HE 2

1 The Second Clinical Medical College of Nanjing Medical University, Nanjing, China; 2 Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China


PDF  REPRINTS


INTRODUCTION: A long non-coding RNA (lncRNA) H19 has been reported to be aberrantly regulated in a wide range of cancers. This meta-analysis was performed to explore the potential value of H19 as a biomarker for cancer prognosis.
EVIDENCE ACQUISITION: We searched the electronic databases PubMed and Web of Science (up to April 30, 2016) in attention to collect all relevant researches to identify the association of lncRNA H19 with overall survival (OS), disease free survival (DFS) and lymph node metastasis (LNM).
EVIDENCE SYNTHESIS: Our findings revealed that high levels of H19 expression could predict poor OS (pooled HR: 1.19, 95% CI: 1.08-1.32, P=0.001) and LNM (pooled OR: 1.810, 95% CI: 1.27-2.59, P=0.001) in multiple cancers.
CONCLUSIONS: This meta-analysis showed that overexpression of H19 might potentially serve as a reliable biomarker for poor prognosis in different types of cancers.

top of page